Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - ENTERING INTO LICENSE AND TRANSFER AGREEMENT2022.04.25
-
ADOPTION OF THE NEW ARTICLES2022.04.25
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2022.04.25
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2022.04.22
-
VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE COOPERATIVE AGREEMENT IN RELATION TO COMBINATION THERAPIES2022.04.21
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2022.04.21
-
VOLUNTARY ANNOUNCEMENT - CATEGORY I ANTI-TUMOR INNOVATIVE DRUG "TQB2930" OBTAINED APPROVAL FOR CLINICAL TRIAL2022.04.20
-
VOLUNTARY ANNOUNCEMENT - “ANLOTINIB HYDROCHLORIDE CAPSULES” OBTAINED APPROVAL FOR THE FIFTH INDICATION2022.04.19